MSK researchers present predictive findings from first use of Mission Bio’s scMRD assay for AML

NCI’s myeloMATCH will use biomarkers to match patients with myeloid cancer to trials

NCI has launched a second-generation precision medicine clinical trial called Myeloid Malignancies Molecular Analysis for Therapy Choice, or myeloMATCH, a trial focused on acute myeloid leukemia and myelodysplastic syndromes.

October 25, 2024

Vol.50 No.40

By Claire Marie Porter

Drugs & Targets

NeoGenomics launches NGS assay for AML

AML Express, a next-generation sequencing assay designed to provide rapid, comprehensive genetic profiling for patients with acute myeloid leukemia, was announced by NeoGenomics Inc.

October 11, 2024

Vol.50 No.38

Conversation with The Cancer Letter

Undergrad intern at MSK poses a profound question: What if Henrietta Lacks had a Black doctor?

Every summer since 2010, ten undergraduate students from diverse backgrounds get the opportunity to explore any curiosities they might have about careers in medicine at Memorial Sloan Kettering Cancer Center.

October 04, 2024

Vol.50 No.37

By Claire Marie Porter

In Brief

Dana-Farber, Fred Hutch, MSK, Hopkins form Cancer AI Alliance

Four NCI-designated cancer centers—Dana-Farber Cancer Institute, Fred Hutch Cancer Center, Memorial Sloan Kettering Cancer Center, and The Sidney Kimmel Comprehensive Cancer Center and Whiting School of Engineering at Johns Hopkins—have joined together and secured funding from AWS, Deloitte, Microsoft, and NVIDIA, to create the Cancer AI Alliance.

October 04, 2024

Vol.50 No.37

Drugs & Targets

FDA grants Fast Track designation for ICT01 + Azacitidine + Venetoclax in treatment of first-line AML unfit for induction chemo

FDA granted Fast Track designation to ICT01 in combination with azacitidine and venetoclax for the treatment of acute myeloid leukemia patients 75 years or older, or who have comorbidities that preclude use of standard intensive induction chemotherapy.

September 20, 2024

Vol.50 No.35

Clinical

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies

A meta-analysis of 25 studies—totaling over 5,000 participants—focused on a question that has been troubling patients, physicians, and regulators: Does treatment with CAR T-cell therapy contribute to the development of secondary cancers?

September 13, 2024

Vol.50 No.34

By McKenzie Prillaman

MSK researchers present predictive findings from first use of Mission Bio’s scMRD assay for AML

YOU MAY BE INTERESTED IN

NCI’s myeloMATCH will use biomarkers to match patients with myeloid cancer to trials

NeoGenomics launches NGS assay for AML

Undergrad intern at MSK poses a profound question: What if Henrietta Lacks had a Black doctor?

Dana-Farber, Fred Hutch, MSK, Hopkins form Cancer AI Alliance

FDA grants Fast Track designation for ICT01 + Azacitidine + Venetoclax in treatment of first-line AML unfit for induction chemo

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies

Renew today!

Subscriber content

Login

MSK researchers present predictive findings from first use of Mission Bio’s scMRD assay for AML

YOU MAY BE INTERESTED IN

NCI’s myeloMATCH will use biomarkers to match patients with myeloid cancer to trials

NeoGenomics launches NGS assay for AML

Undergrad intern at MSK poses a profound question: What if Henrietta Lacks had a Black doctor?

Dana-Farber, Fred Hutch, MSK, Hopkins form Cancer AI Alliance

FDA grants Fast Track designation for ICT01 + Azacitidine + Venetoclax in treatment of first-line AML unfit for induction chemo

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis showsSubgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies

Login

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies